Approximately 70% of patients have ER-positive, HER2-negative breast cancer (3), and the combination of endocrine therapy and a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor is one of the standard treatments for this subtype (4–7). Here, ESR1 is linked to breast carcinoma.